Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Apr 1;75(4):488-494.
doi: 10.1001/jamaneurol.2017.4325.

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease

Affiliations
Observational Study

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease

Yen Ying Lim et al. JAMA Neurol. .

Abstract

Importance: Older age, high levels of β-amyloid (Aβ), and the presence of the apolipoprotein E (APOE) ε4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined.

Objective: To determine the association of age, Aβ level, and APOE ε4 with memory decline in a large group of cognitively healthy older adults.

Design, setting, and participants: This longitudinal observational study included cognitively healthy older adults (age >60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent Aβ imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable.

Exposures: β-Amyloid imaging using positron emission tomography, genotyping for APOE ɛ4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up.

Main outcomes and measures: Episodic memory composite score.

Results: Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each Aβ-ɛ4 group (24 of 51 Aβ-positive ε4 noncarriers [47.1%] ; 35 of 64 Aβ-negative ε4 carriers [54.7%]; 40 of 72 Aβ-positive ε4 carriers [55.6%]; and 145 of 260 Aβ-negative ε4 noncarriers [55.8%]). Adults with Aβ findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for Aβ (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from Aβ-negative ɛ4 noncarriers at an earlier age in Aβ-positive ɛ4 carriers (64.5 years) than in Aβ-positive ɛ4 noncarriers (76.5 years), such that by 85 years of age, Aβ-positive ε4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than Aβ-negative ε4 noncarriers and approximately 0.8 SD units worse than Aβ-positive ε4 noncarriers. Memory performance of Aβ-negative ɛ4 carriers did not differ from that of the Aβ-negative ɛ4 noncarriers (estimate [SE], 0.001 [0.001]; t = 0.526; P = .77).

Conclusions and relevance: Prior work has shown that Aβ and ε4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with Aβ and ε4 at each age.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lim reports serving as a scientific consultant to CogState, Ltd, Biogen, and Lundbeck. Dr Pietrzak reports serving as a scientific consultant to CogState, Ltd. Dr Villemagne reports serving as a consultant for Bayer Pharma and receiving research support from a New Energy and Industrial Technology Development Organization grant from Japan. Dr Masters reports serving as an advisor to Prana Biotechnology, Ltd, and a consultant to Eli Lilly and Company. Dr Rowe reports serving on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare, and AstraZeneca; receiving speaker honoraria from Bayer Pharma and GE Healthcare; and receiving research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences, and Avid Radiopharmaceuticals not related to the content of the manuscript. No other disclosures were reported.

Figures

Figure.
Figure.. Standardized Score on the Episodic Memory Composite by Age
Scores range from −3.51 to 1.93, with higher scores indicating better performance. Quadratic rates of change in episodic memory are shown for each β-amyloid (Aβ)–negative and Aβ-positive group by apolipoprotein E ε4 allele carrier status. Shading indicates 95% CIs of slope.

Comment in

References

    1. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349. - PubMed
    1. Lim YY, Maruff P, Pietrzak RH, et al. ; AIBL Research Group . Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain. 2014;137(pt 1):221-231. - PubMed
    1. Doraiswamy PM, Sperling RA, Johnson K, et al. ; AV45-A11 Study Group; AV45-A11 Study Group . Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051. - PMC - PubMed
    1. Doré V, Villemagne VL, Bourgeat P, et al. . Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013;70(7):903-911. - PubMed
    1. Villemagne VL, Burnham S, Bourgeat P, et al. ; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group . Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367. - PubMed

Publication types

MeSH terms